CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.9B, above the global median of $1.18B
- FinancialsAltman Z-Score 4.1: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.90BUSDvs all stocks (USD)
Revenue (TTM)
104.97MUSDvs all stocks (USD)
Profit Margin
-155.59%vs Biotechnology peers
Beta
0.8830xvs all stocks
52-Week Change
121.65%vs all stocks
Market Capitalization
1.90BUSDvs all stocks (USD)
Enterprise Value
1.48BUSDvs all stocks (USD)
Forward P/E
-6.71xvs Biotechnology peers
Price to Sales (TTM)
16.86xvs Biotechnology peers
Price to Book (MRQ)
3.52xvs Biotechnology peers
Enterprise to Revenue
14.13xvs Biotechnology peers
Enterprise to EBITDA
-7.20xvs Biotechnology peers
Profit Margin
-155.59%vs Biotechnology peers
Operating Margin
-72.37%vs Biotechnology peers
Return on Assets (TTM)
-16.84%vs Biotechnology peers
Return on Equity (TTM)
-29.07%vs Biotechnology peers
Revenue (TTM)
104.97MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.40USDUpdated Sep 28, 2026Quarterly Revenue Growth
17.50%vs Biotechnology peers
Gross Profit (TTM)
-150.79MUSDvs all stocks (USD)
EBITDA (TTM)
-205.90MUSDvs all stocks (USD)
Net Income (TTM)
-163.32MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
17.46%vs Biotechnology peers
Operating Cash Flow (TTM)
-205.81MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-94.54MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
0.00USDFY2025 · Dec 31, 2025Revenue
125.58MUSDFY2025 · Dec 31, 2025Operating Income
-177.50MUSDvs all stocks (USD)
Pre-tax Income
-89.63MUSDFY2025 · Dec 31, 2025Income Tax Expense
2.50MUSDFY2025 · Dec 31, 2025Net Income
-92.14MUSDFY2025 · Dec 31, 2025EBIT
-57.71MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-139.54MUSDFY2025 · Dec 31, 2025Research & Development
239.43MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
63.64MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
27.52MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
31.93MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.24USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.24USDFY2025 · Dec 31, 2025Basic Shares Outstanding
74.24MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
74.24MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-92.14MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
214.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
-62.53MUSDFY2025 · Dec 31, 2025Free Cash Flow
-65.68MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
54.36MUSDFY2025 · Dec 31, 2025Income Tax Paid
7.31MUSDFY2025 · Dec 31, 2025Interest Paid
5.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-92.14MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
10.51MUSDFY2025 · Dec 31, 2025Stock-based Compensation
43.23MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-48.34MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
31.36MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-3.95MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.19MUSDFY2025 · Dec 31, 2025Capital Expenditures
-3.15MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-298.89MUSDFY2025 · Dec 31, 2025Sale of Investments
442.03MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
139.99MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.73MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.73MUSDFY2025 · Dec 31, 2025Shares Outstanding
74.33MSharesUpdated Sep 28, 2026Float Shares
54.25MSharesUpdated Sep 28, 2026Shares Short
15.75MSharesUpdated Sep 28, 2026Short Ratio
11.18daysvs all stocks
Short % of Shares Outstanding
30.05%vs all stocks
% Held by Insiders
1.22%vs all stocks
% Held by Institutions
114.54%vs all stocks
Total Cash (MRQ)
456.45MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.14USDUpdated Sep 28, 2026Total Debt (MRQ)
170.11MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.3380xvs Biotechnology peers
Current Ratio (MRQ)
6.39xvs Biotechnology peers
Book Value per Share (MRQ)
6.77USDUpdated Sep 28, 2026Total Assets
875.50MUSDvs all stocks (USD)
Total Current Assets
599.82MUSDFY2025 · Dec 31, 2025Total Liabilities
239.91MUSDFY2025 · Dec 31, 2025Total Non-current Assets
275.67MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
144.00MUSDFY2025 · Dec 31, 2025Total Current Liabilities
95.91MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
54.07MUSDFY2025 · Dec 31, 2025Other Short-term Investments
493.66MUSDFY2025 · Dec 31, 2025Accounts Receivable
29.30MUSDFY2025 · Dec 31, 2025Accounts Payable
10.83MUSDFY2025 · Dec 31, 2025Short-term Debt
46.53MUSDFY2025 · Dec 31, 2025Long-term Debt
141.22MUSDFY2025 · Dec 31, 2025Common Stock (Book)
718.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-795.96MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
635.59MUSDvs all stocks (USD)
52-Week Low
10.38USDUpdated Sep 28, 202652-Week High
30.61USDUpdated Sep 28, 202652-Week Change
121.65%vs all stocks
Beta
0.8830xvs all stocks
50-Day MA
23.59USDUpdated Sep 28, 2026200-Day MA
15.68USDUpdated Sep 28, 2026Avg 10-Day Volume
1.60MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.45MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-2.16USDUpdated Sep 28, 2026Other Income / Expense
92.27MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.1: safe zoneNotable
Altman Z-Score: 4.10
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.9B, above the global median of $1.18BNotable
Market cap (USD): 1,903,446,963Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
OneSource Specialty Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
ChemoMetec A/S
Tier 1ProductionApproval-Gated PipelineRule
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Inner Mongolia Furui Medical Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinyu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Mabwell (Shanghai) Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Innostar Bio-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Zymeworks Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fagron NV
Tier 1ProductionApproval-Gated PipelineFlowRule